---
schema_version: "secwatch.filing_event.v1"
accession: "0001378325-26-000035"
form_type: "8-K"
ticker: "CV"
cik: "0001378325"
company_name: "CapsoVision, Inc"
filed_at: "2026-08-13T20:07:15+00:00"
generated_at: "2026-08-13T20:10:56.853941+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CapsoVision Q2 revenue $3.6M (+10% YoY), gross margin 51%, ATM up to $100M

## Summary
- Q2 revenue $3.6M, up 10% YoY; gross margin 51% vs 55% on pricing pressure and tariffs.
- Operating expenses $9.5M, up $3.0M YoY; cash $9.1M at June 30, 2026.
- Entered ATM equity offering up to $100M with Cantor Fitzgerald; 3% commission.
- Launched AI Highlights™ internationally; FDA clearance expected by end of Q3 2026.
- Appointed David S. Shields, M.D. to Board effective July 1, 2026.

## SEC filing metadata
- accession: 0001378325-26-000035
- form_type: 8-K
- ticker: CV
- cik: 0001378325
- company_name: CapsoVision, Inc
- filed_at: 2026-08-13T20:07:15+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/0001378325-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/cv-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001378325-26-000035
- JSON: https://secwatch.observer/filing/0001378325-26-000035.json
- Plain text: https://secwatch.observer/filing/0001378325-26-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.